HuCAL

Type: Product
Name: HuCAL
First reported Jul 28 2014 - Updated 15 hours ago - 1 reports

MorphoSys AG Reports Results for the First Six Months of 2014

(GLOBE NEWSWIRE) -- (FSE: MOR; Prime Standard Segment; TecDAX, OTC: MPSYY) today announced its financial results for the six months ending 30 June 2014. Group revenues from continuing operations were EUR 30.5 million (H1 2013: EUR 48.2 million). Reasons ... [Published Pettinga Financial Advisors - Jul 28 2014]
First reported Jul 28 2014 - Updated Jul 28 2014 - 1 reports

MorphoSys' (MPSYF) CEO Simon Moroney on Q2 2014 Results - Earnings Call Transcript

MorphoSys AG ( OTCPK:MPSYF ) Q2 2014 Earnings Conference Call July 28, 2014 8:00 AM ETOperatorLadies and gentlemen, welcome to the MorphoSys Quarterly Call on the Financial Results of Q2 2014. Please note that for the duration of the presentation, all ... [Published Seeking Alpha - Jul 28 2014]
First reported Jul 28 2014 - Updated Jul 28 2014 - 1 reports

MorphoSys AG Reports Results for the First Six Months of 2014

(GLOBE NEWSWIRE) -- MorphoSys AG (FSE: MOR; Prime Standard Segment; TecDAX, OTC: MPSYY) today announced its financial results for the six months ending 30 June 2014. Group revenues from continuing operations were EUR 30.5 million (H1 2013: EUR 48.2 million). ... [Published Virtual Strategy Magazine - Jul 28 2014]
First reported Jul 28 2014 - Updated Jul 28 2014 - 1 reports

MorphoSys H1 Profit Decreases; Re-confirms Guidance For 2014

MorphoSys AG (MPSYY.PK) reported earnings before interest and taxes (EBIT) from continued operations of 0.4 million euros for the six months ending 30 June 2014, compared to 17.3 million euros, a year ago. Profit from continuing operations decreased to ... [Published RTTNews.com - Jul 28 2014]
First reported Jul 23 2014 - Updated Jul 23 2014 - 1 reports

MorphoSys and Galapagos Advance Joint Antibody Program in Inflammatory Diseases into Preclinical Development

(GLOBE NEWSWIRE) -- MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) and Galapagos NV (Euronext: GLPG; OTC: GLPYY) announced today that the first program from their strategic alliance has advanced into preclinical development. MOR106 ... [Published Virtual Strategy Magazine - Jul 23 2014]
First reported Jul 21 2014 - Updated Jul 21 2014 - 1 reports

MorphoSys to Host Q2 2014 Conference Call on 28 July 2014

World News: 13:35 GMT Monday 21st July 2014 . [ ]This storyMARTINSRIED / MUNICH, Germany, July 21, 2014 (GLOBE NEWSWIRE)MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) will publish its first six months' 2014 results on 28 July 2014 at 7:00 am ... [Published SPi World News - Jul 21 2014]
First reported Jul 18 2014 - Updated Jul 18 2014 - 1 reports

MorphoSys Receives Additional Patents on Novel Antibody Platform Ylanthia in the US and First Patent in China

MorphoSys AG / . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) today announced that the US Patent and Trademark ... [Published BusinessWeek - Jul 18 2014]
First reported Jul 10 2014 - Updated Jul 10 2014 - 1 reports

Lois Laxton dancers ready for Spanish fiesta

| Photo by Mike PearsonCompetitive dancers from Lois Laxton Dance Studio will showcase their skills in Spain this month.By Mike Pearson, News staffIt’s known for its scenic shoreline, the gardens of La Paloma and its cable car views of the Calamorro ... [Published Stoney Creek News - Jul 10 2014]
First reported Jun 17 2014 - Updated Jun 17 2014 - 1 reports

Monoclonal antibodies against ANGPTL3

Monoclonal antibodies that specifically bind to ANGPTL3 are provided. Monoclonal antibodies that neutralize at least one activity of ANGPTL3 are provided. Methods of treating a disorder of lipid metabolism using neutralizing monoclonal antibodies are ... [Published PharmCast - Jun 17 2014]
First reported Feb 18 2014 - Updated Feb 19 2014 - 1 reports

MorphoSys gets clinical milestone from Novartis in anti-inflammatory programme

MorphoSys AG, one of the world's leading biotechnology companies focusing on fully human antibodies, has received a milestone payment from Novartis in connection with the clinical trial application (CTA/IND) and projected initiation of a phase I clinical ... [Published PharmaBiz - Feb 18 2014]

Quotes

"The second quarter saw excellent progress with regard to partnering our latest Ylanthia antibody technology. With Merck Serono and the Temple University's Moulder Center for Drug Discovery two new alliances were initiated that have the potential to expand our pipeline of exciting new drug candidates" stated Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG
"The impact of our next-generation antibody technology Ylanthia is increasingly visible in our portfolio. Ylanthia is ideally suited for therapeutic antibody discovery in a variety of fields including immuno-oncology, cancer stem cells and many more. The opportunity created by applying our antibody capabilities in the GPCR target space, for instance, could be enormous and we have just begun to scratch the surface by adding two new GPCR-programs to our portfolio" commented Dr. Marlies Sproll, Chief Scientific Officer of MorphoSys AG
"Our SilenceSelect target discovery platform delivered the novel target against which this antibody is directed. MOR106 is the first antibody in the pipeline of Galapagos, and we are excited to develop this program further in close collaboration with our friends at MorphoSys" commented Onno van de Stolpe, CEO of Galapagos
"Our new antibody platform Ylanthia is being used in a rising number of therapeutic relationships including our recent alliances with Merck Serono and Temple University. In addition to building a track record on the commercial side, robust patent protection is important for our new technology platform and today's patents further strengthen our position around Ylanthia in our core markets and in the emerging markets" commented Dr. Marlies Sproll, Chief Scientific Officer of MorphoSys AG

More Content

All (12) | News (11) | Reports (0) | Blogs (0) | Audio/Video (0) | Fact Sheets (0) | Press Releases (1)
sort by: Date | Relevance
MorphoSys' (MPSYF) CEO Simon Moroney on Q2 2014... [Published Seeking Alpha - Jul 28 2014]
MorphoSys AG Reports Results for the First Six ... [Published Virtual Strategy Magazine - Jul 28 2014]
MorphoSys H1 Profit Decreases; Re-confirms Guid... [Published RTTNews.com - Jul 28 2014]
MorphoSys AG Reports Results for the First Six ... [Published GlobeNewswire: Advertising News - Jul 28 2014]
MorphoSys AG Reports Results for the First Six ... [Published Pettinga Financial Advisors - Jul 28 2014]
MorphoSys Provides Update on the Company's Prop... [Published OSIX News - Jul 28 2014]
MorphoSys and Galapagos Advance Joint Antibody ... [Published Virtual Strategy Magazine - Jul 23 2014]
MorphoSys to Host Q2 2014 Conference Call on 28... [Published SPi World News - Jul 21 2014]
MorphoSys Receives Additional Patents on Novel ... [Published BusinessWeek - Jul 18 2014]
Lois Laxton dancers ready for Spanish fiesta [Published Stoney Creek News - Jul 10 2014]
Monoclonal antibodies against ANGPTL3 [Published PharmCast - Jun 17 2014]
MorphoSys gets clinical milestone from Novartis... [Published PharmaBiz - Feb 18 2014]
1
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Press Releases

sort by: Date | Relevance
MorphoSys AG Reports Results for the First Six ... [Published GlobeNewswire: Advertising News - Jul 28 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.